|Bid||10.31 x 1100|
|Ask||10.36 x 800|
|Day's Range||10.12 - 10.80|
|52 Week Range||2.10 - 14.62|
|Beta (5Y Monthly)||1.72|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 11, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.00|
On the call with me is Dr. Todd Brady, president and chief executive officer. Forward-looking statements include statements regarding the timing of planned clinical trial initiations, Aldeyra's possible or assumed future results of operations, expenses and financial position, business strategies and plans, research, development and commercial plans or expectations, trends, market sizing, competitive position, industry environment and potential growth opportunities, among other things.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today reported business highlights and financial results for the year ended December 31, 2020.
NEW YORK, NY / ACCESSWIRE / March 11, 2021 / Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 11, 2021 at 8:00 AM Eastern Time.